14 January 2022: CYK Partner Sam Roberts writes for Investment Monitor on the difficulties of investing in medtech as highlighted by the recent guilty verdict reached in the Theranos trial. See link here for full article.
We use cookies on our website. By using this website, you agree that we can set and use these cookies. To learn more about cookies, including how we use them and how to change your cookie settings, please see our cookie policy.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
+44 (0)20 7148 7800
LinkedIn
Twitter
Email
Print